Utility of toluidine blue in oral premalignant lesions and squamous cell carcinoma: Continuing research and implications for clinical practice

Authors

  • Joel B. Epstein DMD, MSD, FRCD(C),

    Corresponding author
    1. Department of Oral Medicine and Diagnostic Sciences, College of Dentistry, University of Illinois, Chicago, Illinois
    2. Interdisciplinary Program in Oral Cancer, College of Medicine, University of Illinois, Chicago, Illinois
    • Department of Oral Medicine and Diagnostic Sciences, College of Dentistry, University of Illinois, Chicago, Illinois
    Search for more papers by this author
  • James Sciubba DMD, PhD,

    1. The Johns Hopkins School of Medicine, Baltimore, Maryland
    Search for more papers by this author
  • Sol Silverman Jr. MA, DDS,

    1. Oral Medicine, University of California San Francisco, San Francisco, California
    Search for more papers by this author
  • Herve Y. Sroussi DMD, PhD

    1. Department of Oral Medicine and Diagnostic Sciences, College of Dentistry, University of Illinois, Chicago, Illinois
    Search for more papers by this author

Abstract

Toluidine blue (TB) has been shown to aid in the detection and diagnosis of oropharyngeal squamous cell carcinoma (OSCC) and oral premalignant lesions (OPLs). TB has been shown to enhance visualization of oral lesions and assist in identifying sites of increased risk of dysplastic/malignant change and promote biopsy. TB has been shown to identify lesions with molecular changes associated with risk of progression of OPLs to OSCC. A recent prospective longitudinal study showed TB retention in histologic benign lesions and lesions with mild dysplasia that are at increased risk of progression to cancer. Clinical trials show that TB is useful in identifying asymptomatic OSCC and premalignant lesions at risk of progressing to SCC, which might otherwise be undetected until lesions become more advanced. The data supports TB use in oral examination of patients at risk of OSCC. © 2007 Wiley Periodicals, Inc. Head Neck 2007

Ancillary